| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() ICN Test to Detect Hereditary Disorders in Newborns COSTA MESA, Calif., Jan. 23, 1996 - ICN Pharmaceuticals, Inc. (NYSE: ICN) announced that it has received authorization from the Food and Drug Administration (FDA) to market an important new test for Galactosemia in newborn infants. Galactosemia is a hereditary metabolic disorder found in infants, which may affect one in 30,000 newborns. The ICN test is a quantitative enzyme assay in a microplate format. ICN's test provides a convenient alternative to the earlier screening tests utilizing bacteria, particularly in offering enhanced assay performance, automation and same-day results. Early diagnosis allows doctors to quickly prescribe galactose-free diets in order to reduce the levels of the sugar circulating in the infant's blood. Classical galactosemia in infants, left untreated, is characterized by enlargement and subsequent damage to the liver and brain, cataract formation, and failure to thrive. Testing for galactosemia is becoming increasingly mandatory throughout the United States. ICN will begin marketing the test immediately. ICN Pharmaceuticals, Inc. is a worldwide healthcare company that manufactures, markets and distributes a range of prescription and non-prescription pharmaceuticals, biotechnology research products and medical diagnostics. CONTACT: Jennifer Openshaw of ICN, 714-545-0100, ext. 2202 (ICN)
|